Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer

NCT05335993 is registered in ClinicalTrials.gov with CanariaBio Inc. as lead sponsor.

NCT NCT05335993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05335993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer
Lead sponsor
CanariaBio Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 25, 2022
Completion date
December 30, 2027
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of ovary, peritoneal cancer, recurrent carcinoma of ovary, recurrent epithelial cancer of ovary, recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, recurrent ovarian cancer